Cannara Biotech (LOVE) Q2 2025 earnings summary

Executive summary

• Achieved record Q2 2025 results with net revenues of CAD 26.6 million (USD $26.6M), up 35% year over year, driven by national brand growth and product innovation.

• Delivered record gross profit, gross margin, operating income, and adjusted EBITDA, marking the 16th consecutive quarter of positive adjusted EBITDA and fourth consecutive quarter of positive net income.

• Operates two large-scale Quebec-based cultivation facilities, with expansion plans to increase capacity to 100,000kg annually.

• Maintains a clean balance sheet with ample cash flows, no significant near-term debt maturities, and extended credit facilities.

• Strong brand presence with flagship brands Tribal, Nugz, and Orchid CBD, each leading in their respective product categories.

Financial highlights

• Q2 FY2025 net revenues reached CAD 26.6 million, gross profit before fair value adjustments at CAD 10.8 million, and adjusted EBITDA at CAD 7.1 million.

• Gross margin for Q2 FY2025 was 41%, a 170 basis point improvement quarter over quarter and 370 basis points year over year.

• Net income for Q2 was CAD 3.3 million, with EPS of CAD 0.004, and year-to-date net income was $5.6 million, reversing a prior year loss.

• Year-to-date total revenue was $51.7 million, with YTD gross profit of $20.6 million and YTD adjusted EBITDA of $13.1 million.

• Cash on hand at quarter-end was $5.1 million, with working capital of $43.2 million.

Outlook and guidance

• Production capacity expected to increase to 39,500kg in FY25 and 50,000kg in FY26, with a long-term goal of 100,000kg.

• Plans to activate two new grow zones in 2025, adding 6,000kg to annual capacity and expanding active canopy to over 300,000 sq. ft.

• Over 20 product launches planned for 2025, including proactive development of vape products for Quebec ahead of regulatory changes.

• Forecasts growth in net revenue and adjusted EBITDA for fiscal 2025, with continued positive operating and free cash flow on an annualized basis.

• No immediate plans for international expansion; focus remains on Canadian market dominance.